Sociodemographic Disparities in the Diagnosis and Prognosis of Patients With Cervical Cancer: An Analysis of the Surveillance, Epidemiology, and End Results Program.
cervical cancer
disparities
ethnicity
hysterectomy
prognosis
race
socioeconomic status
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
04
07
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
epublish
Résumé
Background While the incidence and mortality rates of cervical cancer are declining due to improved prevention, screening, and treatment, inequitable access to care may contribute to worse patient outcomes. Therefore, we sought to evaluate sociodemographic disparities in the diagnosis and prognosis of patients with cervical cancer. Methodology The Surveillance, Epidemiology, and End Results (SEER) database was queried for adult women diagnosed with cervical cancer from 2010 to 2015. Sociodemographic groups of interest included patient race/ethnicity (non-Hispanic White/Hispanic White/Black/Other), residential setting (rural/urban), and county median household income (<$45,000/$45,000-59,999/$60,000-74,999/≥$75,000). Outcomes of interest included stage at diagnosis, receipt of hysterectomy, and overall survival (OS). Outcomes were evaluated using Pearson's chi-square test, multivariable logistic regression, and multivariable Cox proportional hazards. Results A total of 5,726 patients were identified with an average age of 50.1 years (SD = 14.6). Significant differences in cancer stage at diagnosis were identified based on race/ethnicity (p < 0.001) and household income (p = 0.012). On adjusted analysis, Black patients were found to be significantly less likely to receive a hysterectomy compared to non-Hispanic White patients (odds ratio (OR) = 0.46; 95% confidence interval (CI) = 0.37-0.56). Lower household income was associated with poorer survival for stage I (<$45,000 vs. >$75,000: hazard ratio (HR) = 1.53; 95% interquartile range (IQR) = 1.00-2.33), II ($45,000-59,999 vs. >$75,000: HR = 1.67; 95% IQR = 1.19-2.35), and IV (<$45,000 vs. >$75,000: HR = 1.64; 95% IQR = 1.22-2.29) disease. Black race was associated with poorer OS for stage IV disease (HR = 1.29; 95% IQR = 1.06-1.56). Conclusions This study highlights significant disparities in disease progression at diagnosis and OS for cervical cancer patients based on race/ethnicity and household income. These findings may assist policymakers in developing strategies for mitigating these disparities.
Identifiants
pubmed: 37551220
doi: 10.7759/cureus.41477
pmc: PMC10404158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e41477Informations de copyright
Copyright © 2023, Zreik et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Natl Med Assoc. 2020 Apr;112(2):229-232
pubmed: 32278478
Gynecol Oncol. 2014 Jan;132(1):254-9
pubmed: 24041877
IARC Sci Publ. 1997;(138):369-76
pubmed: 9353678
MMWR Surveill Summ. 2017 Jul 07;66(14):1-13
pubmed: 28683054
Med Clin North Am. 2020 Nov;104(6):1063-1078
pubmed: 33099451
Gynecol Oncol. 1999 Oct;75(1):113-7
pubmed: 10502436
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Obstet Gynecol Clin North Am. 2007 Dec;34(4):739-60, ix
pubmed: 18061867
PLoS One. 2017 Feb 24;12(2):e0172548
pubmed: 28234949
Prev Chronic Dis. 2019 Jun 06;16:E70
pubmed: 31172917
J Obstet Gynecol Neonatal Nurs. 2014 Sep-Oct;43(5):580-588
pubmed: 25139164
BMJ Open. 2019 Jan 24;9(1):e026292
pubmed: 30679300
MMWR Morb Mortal Wkly Rep. 2014 Nov 7;63(44):1004-9
pubmed: 25375072
Gynecol Oncol. 2021 Nov;163(2):305-311
pubmed: 34454725
Am J Clin Oncol. 2018 Oct;41(10):1024-1027
pubmed: 29028642
Acta Obstet Gynecol Scand. 2017 Feb;96(2):150-157
pubmed: 27861705
Cancer Control. 2018 Jan-Dec;25(1):1073274818789355
pubmed: 30021466
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1265-1274
pubmed: 28751476
Cancer. 2017 May 15;123(6):1044-1050
pubmed: 28112816
Epidemiology. 2013 Jan;24(1):1-9
pubmed: 23211345
Cancer Causes Control. 2013 Nov;24(11):1985-94
pubmed: 23934001
Cancer. 2014 Dec 1;120 Suppl 23:3755-7
pubmed: 25412387
Int J MCH AIDS. 2012;1(1):17-30
pubmed: 27621956
Vaccine. 2007 Apr 20;25(16):3007-13
pubmed: 17292517
Acta Cytol. 2016;60(6):518-526
pubmed: 27825171